Aragen Launches First Phase of Biologics Facility in India
Aragen, a CRDMO, has launched the first phase of its biologics manufacturing facility in Bangalore, India. The $30 million project, executed by its subsidiary Aragen Biologics Pvt Ltd, has completed its first small-scale manufacturing project for a US-based organization, producing a novel anticancer monoclonal antibody.
Aragen's non-GMP facility can handle batch sizes up to 50 liters and includes labs for process development and analytical support.
Manni Kantipudi, CEO Aragen Life Sciences and Director of Aragen Biologics Pvt Ltd. commented, “We are happy to announce the commissioning of the first phase of our biologics manufacturing facility at Bangalore, India as per schedule and the successful completion of the first project at this facility. This brings us one step closer to offering full-scale Gene-to GMP solutions to our customers. Once the facility’s expansion is fully operational by the end of this calendar year, we will be able to do internal tech transfer from our R&D labs in California to the manufacturing site in India, thereby enabling end-to-end integrated service offering to customers.”
Aragen currently offers discovery and development research services including cell line development, upstream and downstream development, protein science, and antibody discovery, from its R&D labs in California, USA. The biologics manufacturing facility at Bangalore will complement these services and enable GMP and non-GMP manufacturing. It will have advanced single-use bioreactors with capacities ranging from 50-2000 L and offer integrated solutions including process development, process validation, analytical development, small-scale manufacturing, large-scale DS manufacturing, and stability services. It will develop and manufacture mAbs, therapeutic proteins, and fusion proteins to augment the company’s bioproduction capability in California.
